tiprankstipranks
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
US Market
TRVI
Trevi Therapeutics
RESEARCH TOOLSreports

Trevi Therapeutics (TRVI) Stock News & Sentiment

589 Followers
Trevi Therapeutics Maps Phase III Path and Runway
Premium
Company Announcements
Trevi Therapeutics Maps Phase III Path and Runway
22d ago
TRVI
TRVI Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
TRVI Earnings this Week: How Will it Perform?
26d ago
TRVI
Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials
Premium
Company Announcements
Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials
1M ago
8K
TRVI
De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough
Premium
Ratings
De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough
1M ago
TRVI
Advancing Haduvio in IPF-Related Chronic Cough: FDA-Endorsed Phase 3 Path and Strong Cash Position Underscore Undervalued Multibillion-Dollar Opportunity for Trevi
Premium
Ratings
Advancing Haduvio in IPF-Related Chronic Cough: FDA-Endorsed Phase 3 Path and Strong Cash Position Underscore Undervalued Multibillion-Dollar Opportunity for Trevi
1M ago
TRVI
Trevi Therapeutics: Favorable Risk-Reward as Haduvio Advances Toward Pivotal Chronic Cough Programs and Billion-Dollar Revenue Potential
Premium
Ratings
Trevi Therapeutics: Favorable Risk-Reward as Haduvio Advances Toward Pivotal Chronic Cough Programs and Billion-Dollar Revenue Potential
3M ago
TRVI
Trevi Therapeutics Appoints New Chief Financial Officer
Premium
Company Announcements
Trevi Therapeutics Appoints New Chief Financial Officer
4M ago
8K
TRVI
More TRVI News >

TRVI News on the Web

Trevi Therapeutics price target lowered to $24 from $25 at JonesResearch
TipRanks News
Bullish
Analysts Conflicted on These Healthcare Names: Trevi Therapeutics (TRVI), Annexon Biosciences (ANNX) and Medtronic (MDT)
TipRanks News
Bullish
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Protagonist Therapeutics (PTGX) and Trevi Therapeutics (TRVI)
TipRanks News
Bullish
Trevi Therapeutics Maps Phase III Path and Runway
TipRanks News
Neutral
Trevi Therapeutics (TRVI) Earnings Transcript
The Motley Fool
Neutral
Trevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley
TipRanks News
Bullish
Cantor Fitzgerald Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)
TipRanks News
Bullish
Trevi Therapeutics (TRVI) Receives a Buy from Stifel Nicolaus
TipRanks News
Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is TRVI’s Media Buzz Sentiment?
Currently, no data Available
What is TRVI’s weekly average amount of articles?
Currently, no data Available
What is TRVI’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
NBIXNeurocrine
STAAStaar Surgical
AORTArtivion
OWLTOwlet
HUMHumana
Showing the stocks with the most bullish news sentiment over the past week